3 research outputs found
Factors associated with non-completion of and scores on physical capability tests in health surveys: The North Health in Intellectual Disability Study
Background - This study investigated the completion rates, scores and factors associated with non-completion and low scores on physical capability tests in a health survey administered to adults with intellectual disabilities.
Method - Assessment comprised body mass index (BMI), the Short Physical Performance Battery (SPPB), the timed up-and-go (TUG) test, the one-legged stance (OLS) test; and gross motor, communication and behavioural functioning tests.
Results - The completion rates among 93 participants (aged 17–78) were 46% for the SPPB, 42% for the TUG, and 31% for the OLS. More severe intellectual disability (OR = 3.12, p
Conclusions - Including physical capability tests in health surveys among adults with intellectual disabilities is important to monitor functional status and guide prevention strategies
The development of life expectancy for people with Down syndrome in Norway,1969–2050
Bakgrunn: Levealderen for personer med Downs syndrom har økt dramatisk på 1900 tallet i hele den vestlige verden. Imidlertid er det få undersøkelser om levealderfor denne populasjonen på 2000-tallet, og vi har ikke funnet noen norske undersøkelser. Hensikt:Undersøkelsen skal gi innsikt i levealdersutvikling i Norge fra 1969 og frem til 2010 og fremtidig forekomst av voksne og eldre med Downs syndrom frem til 2050. Metode:Det er en kvantitativ nasjonal demografisk registerundersøkelse for å beregne levealdersutviklingen for personer med Downs syndrom (n = 2 593). Registerdataene som er samlet inn er kontinuerlige data som er basert på løpende tellinger i den nasjonale fødsels-og dødelighetsstatistikken. Innsamlede data er personer registrert med diagnosekode Downs syndrom, årfødt, år død, alder ved død og kjønn. Hovedresultat:Gjennomsnittlig alder ved død for personer med Downs syndrom fra 1969 til og med 2009 økte fra 16,57 år til 53,40 år. Det var ingen statistisk signifikant forskjell på alder ved død mellom menn og kvinner. Gjennomsnittlig alder ved død for alle som døde etter fylte 40 år i studieperioden økte fra 53,95 år til 58,35 år. Forventet andel personer med Downs syndrom som vil bli 40 år og eldre vil øke fra 52 % for de som blefødt i 1967 til 94 % for de som ble født i 2009. Konklusjon:Levealderen for personer med Downs syndrom har økt betydelig fra 60-tallet og detteskyldes i hovedsak nedgang i spedbarnsdødeligheten. For de som overlever barneårene viser undersøkelsen imidlertid nesten ingen økning i rest levealder i løpet av undersøkelsesperioden. Frem til 2050 kan vi forvente en fordobling av antallet som vil være over 40 årBackground: Life expectancy for people with Down syndrome increased dramatically in the Western worldduringthe 1900s. However, fewsurveys have investigated life expectancy for this population since 2000,none of themNorwegian. Aim: This study aimedt o provide insight into life expectancy for Norwegians with Down syndrome between 1969 and2 010, and to project future rates for adults with Down syndrome until 2050. Method: This quantitative national demographic registry study estimated the development of life expectancy for people with Down syndrome (n = 2,593). To calculate age at death, we collected data from death certificates reported to Statistics Norway.Together with data from Medical Birth Registry,we simulated life tables.Collected data included persons with the diagnosis code for Down syndrome, birth year, year of death, age at death,and sex. Main results:Between 1969 and 2010, mean age at death of persons with Down syndrome increased from 16.57 years to 53.40 years, respectively. We observed no statistically significant difference in age at death between men and women. Average age at death for persons who died after 40 years of age increased from 53.95 years to 58.35 years duringthe study period. We estimated that the percentage of people with Down syndrome older than 40 years of age will increase, from 52% to 94% for those born in 1967 and 2009, respectively. Conclusion:Life expectancy for people with Down syndrome has increased significantly since the 1960s, mainly due to a relative decrease in newborn and infant mortality. Importantly, such individuals who survive childhood showed almost no increase in remaining life expectancy during the study period. By 2050,we expect the number of people with Down syndrome aged 40 or more years to doubleISBN 978-91-86739-73-0</p
Recommended from our members
Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium.
Publication status: PublishedFunder: The Norwegian National Centre for Ageing and HealthFunder: Jérôme Lejeune Foundation, the Wellcome Trust Strategic Award : 098330/Z/12/ZFunder: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Program 1Funder: Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer EuropaFunder: NIHR Applied Research Collaboration East of EnglandINTRODUCTION: People with Down syndrome (DS) have high risk of developing Alzheimer's disease (AD). This study examined mean ages of AD diagnosis and associations with co-occurring conditions among adults with DS from five European countries. METHODS: Data from 1335 people with DS from the Horizon 21 European DS Consortium were used for the analysis. RESULTS: Mean ages of AD diagnosis ranged between 51.4 (SD 7.0) years (United Kingdom) and 55.6 (SD 6.8) years (France). Sleep-related and mental health problems were associated with earlier age of AD diagnosis. The higher number of co-occurring conditions the more likely the person with DS is diagnosed with AD at an earlier age. DISCUSSION: Mean age of AD diagnosis in DS was relatively consistent across countries. However, co-occurring conditions varied and impacted on age of diagnosis, suggesting that improvements can be made in diagnosing and managing these conditions to delay onset of AD in DS. HIGHLIGHTS: Mean age of AD diagnosis was relatively consistent between countries Sleep problems and mental health problems were associated with earlier age of AD diagnosis APOE ε4 carriers were diagnosed with AD at an earlier age compared to non-carriers Number of co-occurring conditions was associated with earlier age of AD diagnosis No differences between level of intellectual disability and mean age of AD diagnosis